Ładuje się......
Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tum...
Zapisane w:
| Wydane w: | J Immunol Res |
|---|---|
| Główni autorzy: | , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Hindawi
2018
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6330826/ https://ncbi.nlm.nih.gov/pubmed/30687767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9580561 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|